Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Azetidines
Cholesterol, LDL
Dose-Response Relationship, Drug
Double-Blind Method
Drug Therapy, Combination
Ezetimibe
Female
Heterozygote
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Male
Middle Aged
Proprotein Convertase 9
Proprotein Convertases
Serine Endopeptidases
Treatment Outcome